FDA Inspection 1264905 — Rivopharm S.A.
The FDA completed an inspection of Rivopharm S.A. on June 23, 2023 in Manno. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- June 23, 2023
- Fiscal Year
- 2023
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Manno (Switzerland)
Additional Details
Mutual Recognition Agreement (MRA)